Medicare Enrolled
Dr. Vijay Gunuganti, M.D.
Medical Oncology · San Antonio, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Gunuganti from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gunuganti? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Gunuganti
Dr. Vijay Gunuganti is a medical oncology in San Antonio, TX, with 19 years in practice. Based on federal Medicare data, Dr. Gunuganti performed 105,773 Medicare services across 3,378 unique beneficiaries.
Between the years covered by Open Payments, Dr. Gunuganti received a total of $1,449,397 from 65 pharmaceutical and/or device companies across 1455 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Gunuganti is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 8% volume in TX$ $1,449,397 industry payments
Medicare Practice Summary
Medicare Utilization ↗105,773
Medicare services
Top 8% in TX for medical oncology
3,378
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,567 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Nivolumab injection (Opdivo) | 22,100 | $23 | $76 |
| Iron infusion (Feraheme) | 17,340 | $0 | $5 |
| Darbepoetin injection (Aranesp) for anemia | 16,150 | $2 | $20 |
| Iron sucrose injection (Venofer) | 12,500 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) | 11,550 | $0 | $5 |
| Denosumab injection (Prolia/Xgeva) | 6,480 | $18 | $66 |
| Contrast dye for imaging (iodine-based) | 3,990 | $0 | $3 |
| Dexamethasone injection (steroid) | 3,426 | $0 | $1 |
| Complete blood count (CBC) with differential | 1,287 | $8 | $36 |
| Blood draw (venipuncture) | 1,209 | $8 | $20 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,140 | $1 | $114 |
| Injection, granisetron hydrochloride, 100 mcg | 1,060 | $0 | $24 |
| Comprehensive metabolic blood panel | 958 | $10 | $64 |
| Office visit, established patient (30-39 min) | 750 | $90 | $368 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 429 | $22 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 401 | $96 | $707 |
| Injection, carboplatin, 50 mg | 366 | $2 | $300 |
| Flow cytometry, additional marker | 323 | $18 | $180 |
| Immunoglobulin level test | 320 | $9 | $56 |
| Chronic care management, first 20 min/month | 256 | $47 | $125 |
| Carcinoembryonic antigen (cea) protein level | 253 | $19 | $99 |
| Drug injection, under skin or into muscle | 240 | $10 | $96 |
| Lactate dehydrogenase (enzyme) level | 234 | $6 | $31 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 222 | $130 | $3,675 |
| PSA test (prostate cancer screening) | 198 | $18 | $94 |
| Measurement of immunoglobulin light chains | 162 | $17 | $60 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 143 | $46 | $313 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 119 | $572 | $1,461 |
| Injection, zoledronic acid, 1 mg | 116 | $7 | $431 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 110 | $53 | $211 |
| Administration of additional new drug or substance into vein, 1 hour or less | 104 | $48 | $344 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 102 | $24 | $145 |
| Injection, diphenhydramine hcl, up to 50 mg | 92 | $1 | $7 |
| Administration of chemotherapy into vein, each additional hour | 89 | $21 | $161 |
| Chronic care management, additional 20 min/month | 89 | $36 | $71 |
| Nursing facility visit, moderate complexity | 86 | $80 | $132 |
| Injection of additional new drug or substance into vein | 85 | $11 | $108 |
| Hospital follow-up visit, high complexity | 85 | $86 | $357 |
| Ferritin level test (iron stores) | 80 | $13 | $60 |
| Iron level test | 80 | $6 | $27 |
| Iron binding capacity test | 80 | $8 | $35 |
| Microscopic examination for white blood cells with manual cell count | 68 | $4 | $22 |
| Complete blood count (CBC), automated | 68 | $6 | $34 |
| Reticulated (young) platelet measurement | 67 | $35 | $143 |
| New patient office visit, complex (60-74 min) | 65 | $149 | $709 |
| Office visit, established patient (20-29 min) | 65 | $62 | $250 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 63 | $1,108 | $4,802 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 57 | $91 | $657 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 56 | $272 | $2,762 |
| Irrigation of implanted venous access drug delivery device | 53 | $17 | $114 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 46 | $178 | $700 |
| Ct scan of chest with contrast | 40 | $48 | $821 |
| Infusion, normal saline solution , 1000 cc | 39 | $2 | $19 |
| CT scan of abdomen and pelvis with contrast | 37 | $168 | $1,067 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 36 | $1 | $17 |
| Basic metabolic blood panel | 29 | $8 | $49 |
| Infusion into a vein for hydration, each additional hour | 27 | $9 | $75 |
| Drawing of blood for a medical problem | 24 | $66 | $264 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 24 | $40 | $78 |
| Initial hospital admission, high complexity | 18 | $124 | $694 |
| New patient office visit (45-59 min) | 17 | $108 | $565 |
| Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | 15 | $139 | $240 |
| Protein measurement, serum | 14 | $11 | $99 |
| Thyroid stimulating hormone (TSH) test | 14 | $16 | $80 |
| Office visit, established patient (10-19 min) | 14 | $40 | $150 |
| Flow cytometry technique for dna or cell analysis, first marker | 13 | $56 | $298 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
17.0% high complexity
75.8% medium
7.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,449,397
Total received (2018-2024)
Avg $207,057/year across 7 years
Top 1% in TX for medical oncology
65
Companies
1,455
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,369,177 (94.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$74,454 (5.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,766 (0.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$211,175
2023$289,496
2022$256,633
2021$169,902
2020$134,478
2019$116,651
2018$271,062
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$389,212
Janssen Pharmaceuticals, Inc
$263,478
Janssen Biotech, Inc.
$195,965
AstraZeneca Pharmaceuticals LP
$94,189
Bayer Healthcare Pharmaceuticals Inc.
$86,279
Bayer HealthCare Pharmaceuticals Inc.
$67,072
Takeda Pharmaceuticals U.S.A., Inc.
$62,136
Amgen Inc.
$56,244
Regeneron Healthcare Solutions, Inc.
$46,370
Merck Sharp & Dohme Corporation
$31,562
INSYS Therapeutics Inc
$23,811
Exelixis Inc.
$14,777
Lilly USA, LLC
$12,119
Tempus AI, Inc
$11,720
Regeneron Pharmaceuticals, Inc.
$9,792
Janssen Scientific Affairs, LLC
$9,259
AMAG Pharmaceuticals, Inc.
$8,380
Coherus Biosciences Inc.
$8,254
GENZYME CORPORATION
$7,504
Ipsen Biopharmaceuticals, Inc
$7,160
Daiichi Sankyo Inc.
$6,077
PFIZER INC.
$5,950
Kite Pharma, Inc.
$4,878
Seattle Genetics, Inc.
$4,442
Astellas Pharma US Inc
$3,329
EMD Serono, Inc.
$3,129
Seagen Inc.
$2,847
Eisai Inc.
$2,711
Karyopharm Therapeutics Inc.
$2,579
Celgene Corporation
$2,120
EISAI INC.
$2,075
Foundation Medicine, Inc.
$875
Myriad Genetic Laboratories, Inc.
$318
Sirtex Medical Inc
$267
Incyte Corporation
$244
Rigel Pharmaceuticals, Inc.
$238
Blueprint Medicines Corporation
$200
Eagle Pharmaceuticals, Inc.
$149
Medtronic, Inc.
$142
Gilead Sciences, Inc.
$141
Genmab U.S., Inc.
$125
ImmunoGen, Inc.
$125
Actelion Pharmaceuticals US, Inc.
$125
Puma Biotechnology, Inc.
$122
Merck Sharp & Dohme LLC
$115
Medtronic Vascular, Inc.
$112
SANOFI-AVENTIS U.S. LLC
$92
Verastem, Inc.
$89
Boehringer Ingelheim Pharmaceuticals, Inc.
$83
Myovant Sciences Inc.
$68
Aveo Pharmaceuticals, Inc.
$53
Novartis Pharmaceuticals Corporation
$32
ARRAY BIOPHARMA INC
$32
Alexion Pharmaceuticals, Inc.
$30
SOBI, INC
$26
JAZZ PHARMACEUTICALS INC.
$22
GE HEALTHCARE
$22
GlaxoSmithKline, LLC.
$20
AVEO Pharmaceuticals, Inc.
$20
Esperion Therapeutics, Inc.
$18
Adaptive Biotechnologies Corporation
$17
MorphoSys, US Inc.
$16
Collegium Pharmaceutical, Inc.
$14
Heron Therapeutics, Inc.
$13
Teva Pharmaceuticals USA, Inc.
$11
Top 3 companies account for 58.6% of total payments
Associated products mentioned in payments ›
AIRSUPRA · ALUNBRIG · AYVAKIT · BAVENCIO · BENDEKA · BLENREP · BRAFTOVI · BREZTRI AEROSPHERE · Bavencio · CABOMETYX · CALQUENCE · CARVYKTI · CYRAMZA · Cabometyx · Copiktra · DARZALEX · Dayvigo · Doptelet · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ERLEADA · EXKIVITY · Elahere · Enhertu · Epkinly · Erleada · FERAHEME · FOTIVDA · FOUNDATIONONE LIQUID · Halaven · HawkOne · IMFINZI · INJECTAFER · INLYTA · JAKAFI · JEVTANA · KEYTRUDA · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LUMAKRAS · LYNPARZA · Lenvima · MONJUVI · NEXLIZET · NINLARO · NO PRODUCT DISCUSSED · Nerlynx · Nplate · Nubeqa · ONIVYDE · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · PADCEV · PEMFEXY · PRECISETUMOR · Pomalyst · PreciseTumor · Prolia · REBLOZYL · RETEVMO · RYBREVANT · Revlimid · Rezlidhia · SARCLISA · SCEMBLIX · SIGNIA · SIR-Spheres Microspheres · SOMATULINE DEPOT · SUBSYS · SUSTOL · SYNDROS · Stivarga · TAGRISSO · TECVAYLI · Tavalisse · Trodelvy · ULTOMIRIS · UPTRAVI · Udenyca · VERZENIO · Vectibix · XALKORI · XARELTO · XGEVA · XPOVIO · XTAMPZA · XTANDI · Xofigo · Yescarta · ZEPZELCA · clonoSEQ · myChoice CDx
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (94%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for medical oncology in TX.
Equivalent to $1,370 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
38
Per 100K population
1.9
County median income
$70,571
Nearest hospital
SOUTH TEXAS SPINE AND SURGICAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Gunuganti is a mixed practice specialist, with above-average Medicare volume (top 8% in TX), and high industry engagement (speaking/promotional, top 1%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Gunuganti experienced with nivolumab injection (opdivo)?
Based on Medicare claims data, Dr. Gunuganti performed 22,100 nivolumab injection (opdivo) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Gunuganti receive payments from pharmaceutical companies?
Yes. Dr. Gunuganti received a total of $1,449,397 from 65 companies across 1,455 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Gunuganti's costs compare to other medical oncologys in San Antonio?
Dr. Gunuganti's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Gunuganti) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in San Antonio
Browse medical oncologys in San Antonio ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
Janssen Pharmaceuticals, Inc Payments to Doctors
See all physicians who received payments from Janssen Pharmaceuticals, Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology